Catalent's Fast Dissolve Technology Used for Allergy Immunotherapy Treatment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent's Fast Dissolve Technology Used for Allergy Immunotherapy Treatment



When Danish pharmaceutical company ALK-Abelló A/S wanted to find a safe, effective delivery method for its Grazax allergy immunotherapy treatment, it applied Catalent’s proprietary Zydis® Bio fast dissolve technology, a unique, freeze-dried oral solid dosage form that dissolves instantly in the mouth. Allergy injection-based therapy had previously remained unchanged for 100 years, requiring monthly sub-cutaneous injection in a clinic.  Catalent’s Zydis Bio technology allowed ALK to successfully launch Grazax as the first “patient friendly” allergen immunotherapy. Administered daily at home, Grazax demonstrated improved tolerability over traditional treatments and delivered increased patient preference and compliance.

With more than 20 products launched in 50 countries, Catalent’s Zydis Fast Dissolve technology continues to be the world’s best in class, orally disintegrating tablet (ODT) technology. Catalent’s Zydis team is highly trained and offers feasibility testing as well as support across the entire product lifecycle. Whether a company is considering an ODT to enhance pharmacokinetics through pre-gastric absorption, looking for a way to improve patient compliance or seeking a marketing advantage for a valued brand, Zydis fast dissolve can help enhance investment value and accelerate a product’s potential.

Catalent Pharma Solutions

www.catalent.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here